In fiscal 2025, which ended Dec 28, 2025, Revvity, Inc reported revenue of $2.9 billion, up 3.7% from the year before. Net income was $241.2 million, a profit margin of 8.4%. Operating income came to $356.6 million, an operating margin of 12.5%. Diluted earnings per share were $2.07. Over the twelve months ended Jul 5, 2026, revenue was $2.9 billion and net income was $237.6 million. Across the 10 fiscal years shown, revenue grew from $2.1 billion in fiscal 2016 to $2.9 billion in fiscal 2025, about 3.4% a year.
USD in millions, except per-share amounts and margins. The percent under a figure is the change from the year before.
| Line |
FY 2026
Jul 5, 2026
|
FY 2025
Dec 28, 2025
|
FY 2024
Dec 29, 2024
|
FY 2023
Dec 31, 2023
|
FY 2022
Jan 1, 2023
|
FY 2021
Jan 2, 2022
|
FY 2020
Jan 3, 2021
|
FY 2019
Dec 29, 2019
|
FY 2018
Dec 30, 2018
|
FY 2017
Dec 31, 2017
|
FY 2016
Jan 1, 2017
|
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
2,912
+4.1%
|
2,856
+3.7%
|
2,755
+0.2%
|
2,751
-16.9%
|
3,312
-13.5%
|
3,828
+43.7%
|
2,663
-7.6%
|
2,884
+3.8%
|
2,778
+23.1%
|
2,257
+6.7%
|
2,116
+0.5%
|
| Cost of revenue |
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
1,437
+102.8%
|
709
+6.6%
|
665
-4.5%
|
| Gross profit |
—
|
—
|
—
|
—
|
1,990
|
—
|
2,110
+51.1%
|
1,396
+4.1%
|
1,341
+24.9%
|
1,074
+6.0%
|
1,013
+5.1%
|
| Research and development |
216
+5.2%
|
216
+9.7%
|
197
-9.1%
|
217
-2.3%
|
222
+10.6%
|
200
+36.8%
|
146
-22.7%
|
189
-2.4%
|
194
+39.1%
|
139
+12.3%
|
124
+10.3%
|
| Selling, general and administrative |
1,026
+4.7%
|
992
-0.2%
|
994
-2.8%
|
1,023
-0.3%
|
1,026
+5.2%
|
975
+36.1%
|
716
-12.1%
|
815
+0.4%
|
812
+29.7%
|
626
+6.0%
|
590
+0.6%
|
| Operating income |
359
-5.5%
|
357
+2.9%
|
347
+15.4%
|
301
-59.5%
|
743
-41.0%
|
1,258
+45.1%
|
867
+139.6%
|
362
+11.8%
|
324
+9.6%
|
296
+0.4%
|
295
+17.4%
|
| Other income (expense) |
-98
-53.4%
|
-88
-188.6%
|
-31
+74.0%
|
-118
-29.4%
|
-91
-65.6%
|
-55
+18.3%
|
-67
+46.2%
|
-125
-88.6%
|
-66
-6101.9%
|
1
+102.2%
|
-51
-19.9%
|
| Pretax income |
261
-17.5%
|
268
-15.1%
|
316
+72.8%
|
183
-71.9%
|
652
-45.8%
|
1,204
+32.8%
|
906
+282.2%
|
237
-8.0%
|
258
-13.2%
|
297
+21.6%
|
244
+16.9%
|
| Income tax |
23
-37.2%
|
28
-14.1%
|
33
+851.8%
|
3
-97.5%
|
139
-55.7%
|
314
+85.3%
|
170
+1705.4%
|
9
-53.5%
|
20
-85.5%
|
140
+393.0%
|
28
+41.7%
|
| Net income |
238
-16.7%
|
241
-10.8%
|
270
-61.0%
|
693
+21.8%
|
569
-39.7%
|
943
+29.6%
|
728
+219.9%
|
228
-4.4%
|
238
-18.7%
|
293
+24.9%
|
234
+10.3%
|
| Basic EPS |
2.10
-11.2%
|
2.07
-6.3%
|
2.21
-60.3%
|
5.56
+23.3%
|
4.51
-44.5%
|
8.12
+24.5%
|
6.52
+216.5%
|
2.06
-4.2%
|
2.15
-19.5%
|
2.67
+24.8%
|
2.14
+13.2%
|
| Diluted EPS |
2.10
-11.2%
|
2.07
-5.9%
|
2.20
-60.4%
|
5.55
+23.3%
|
4.50
-44.3%
|
8.08
+24.5%
|
6.49
+218.1%
|
2.04
-4.2%
|
2.13
-19.3%
|
2.64
+24.5%
|
2.12
+13.4%
|
| Weighted average shares, basic |
113
-6.2%
|
117
-5.1%
|
123
-1.6%
|
125
-1.2%
|
126
+8.6%
|
116
+4.2%
|
112
+0.6%
|
111
+0.2%
|
111
+0.6%
|
110
+0.3%
|
109
-2.7%
|
| Weighted average shares, diluted |
113
-6.2%
|
117
-5.1%
|
123
-1.6%
|
125
-1.3%
|
126
+8.4%
|
117
+4.1%
|
112
+0.5%
|
112
-0.0%
|
112
+0.6%
|
111
+0.5%
|
110
-2.6%
|
| Other measures | |||||||||||
| Depreciation and amortization |
412
-0.2%
|
405
-5.3%
|
428
-0.9%
|
432
+1.1%
|
427
+37.1%
|
311
+54.4%
|
202
-5.8%
|
214
+18.5%
|
181
+72.0%
|
105
+5.0%
|
100
-5.1%
|
| EBITDA |
771
-2.7%
|
762
-1.6%
|
775
+5.8%
|
732
-37.4%
|
1,170
-25.5%
|
1,570
+46.9%
|
1,069
+85.6%
|
576
+14.2%
|
504
+25.9%
|
401
+1.5%
|
395
+10.7%
|
| Interest coverage |
3.82x
|
3.87x
|
3.60x
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
| Margins | |||||||||||
| Gross margin |
—
|
—
|
—
|
—
|
60.08%
|
—
|
79.22%
|
48.41%
|
48.27%
|
47.57%
|
47.90%
|
| Operating margin |
12.32%
|
12.49%
|
12.59%
|
10.93%
|
22.43%
|
32.88%
|
32.56%
|
12.55%
|
11.66%
|
13.10%
|
13.92%
|
| Pretax margin |
8.96%
|
9.39%
|
11.47%
|
6.65%
|
19.68%
|
31.44%
|
34.03%
|
8.22%
|
9.28%
|
13.15%
|
11.54%
|
| Profit margin |
8.16%
|
8.45%
|
9.81%
|
25.20%
|
17.19%
|
24.64%
|
27.33%
|
7.89%
|
8.56%
|
12.97%
|
11.08%
|
| EBITDA margin |
26.48%
|
26.68%
|
28.12%
|
26.62%
|
35.32%
|
41.01%
|
40.14%
|
19.97%
|
18.16%
|
17.75%
|
18.65%
|
| Effective tax rate |
8.97%
|
10.58%
|
10.46%
|
1.90%
|
21.35%
|
26.10%
|
18.70%
|
3.96%
|
7.84%
|
47.12%
|
11.62%
|
How these figures are calculated
Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions, except per-share amounts and margins. Weighted average shares are in millions. Interest expense and finance costs are positive costs. A negative amount on a gain (loss) or income (expense) line is a loss or an expense. EBITDA is operating income plus depreciation and amortization. Interest coverage is operating income divided by interest expense. The first column is the trailing twelve months through the latest quarter. More on our methodology.
New to this? Read How to Read an Income Statement, With a Real Example.
Company profile
- Industry
- Laboratory Analytical Instruments (SIC 3826)
- Listed as
- RVTY (NYSE)
- Fiscal year ends
- December 29
- Incorporated in
- MA
- Headquarters
- Waltham, MA
- SEC filer status
- Large accelerated filer
- SEC CIK
- 31791
- Former names
- PERKINELMER INC (until Apr 14, 2023); EG&G INC (until Jul 26, 1999)
Other Laboratory Analytical Instruments companies
- Agilent Technologies, Inc. A
- Waters Corp /DE/ WAT
- Illumina, Inc. ILMN
- Mettler Toledo International INC/ MTD
- Avantor, Inc. AVTR
- Bio-Rad Laboratories, Inc. BIO
- Bruker Corp BRKR
- 10x Genomics, Inc. TXG
Source: SEC EDGAR filings. This is company-reported data, not investment advice.